A dedicated clinic for HIV-positive individuals over 50 years of age: A multidisciplinary experience

International Journal of STD and AIDS

Volumn 23, Issue 8, 2012, Pages 546-552

  Waters, L ^a   Patterson, B ^a   Scourfield, A ^a   Hughes, A ^a   de Silva, S ^a   Gazzard, B ^a   Barton, S ^a   Asboe, D ^a   Pozniak, A ^a   Boffito, M ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Ageing with HIV; HIV infection; Multidisciplinary HIV clinic

Indexed keywords

AMLODIPINE; ATAZANAVIR PLUS RITONAVIR; CALCIUM; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; NEVIRAPINE; OMEPRAZOLE; PROSTATE SPECIFIC ANTIGEN; SIMVASTATIN; TENOFOVIR;

ADULT; AGED; ANTIVIRAL THERAPY; BONE DENSITY; CLINICAL PROTOCOL; CORONARY ARTERY; DRUG MONITORING; FEMALE; GENERAL PRACTITIONER; HEALTH CARE QUALITY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CARE; NEUROLOGIC EXAMINATION; NURSE PRACTITIONER; OSTEOPENIA; OSTEOPOROSIS; PATIENT COMPLIANCE; PATIENT SATISFACTION; PHARMACIST; POLYPHARMACY; PRIORITY JOURNAL; PSYCHOMETRY; REVIEW; SCREENING;

AGE FACTORS; AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; ANTI-HIV AGENTS; BONE DENSITY; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; LONDON; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PATIENT CARE TEAM;

EID: 84865831511     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2012.011412     Document Type: Review

References (42)

1. Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One 2011;6:e22698
2. Lewden C, Chene G, Morlat P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46:72-7
3. Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis 2011;53:1130-9
4. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-9
5. Smith RD, Delpech VC, Brown AE, Rice BD. HIV transmission and high rates of late diagnoses among adults aged 50 years and over. AIDS 2010;24:2109-15
6. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta: US Department of Health and Human Services, Centers for Disease Control and Prevention, 2009. See http://www.cdc.gov/hiv/ surveillance/resources/reports/2007report (last checked 12 July 2012)
7. Sherr L, Lampe FC, Clucas C, et al. Self-reported non-adherence to ART and virological outcome in a multiclinic UK study. AIDS Care 2010;22:939-45
8. Sabin CA, Smith CJ, D'rminio Monforte A, et al. Response to combination antiretroviral therapy: variation by age. AIDS 2008;22:1463-73
9. Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997;61:331-9
10. Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther 2010;15:413-23
11. Benn PD, Miller RF, Evans L, Minton J, Edwards SG. Devolving of statin prescribing to general practitioners for HIV-infected patients receiving antiretroviral therapy. Int J STD AIDS 2009;20:202-4
12. Kaplan RC, Sinclair E, Landay AL, et al. T cell activation and senescence predict subclinical carotid artery disease in HIV-infected women. J Infect Dis 2011;203:452-63
13. Rodkjaer L, Laursen T, Balle N, Sodemann M. Depression in patients with HIV is under-diagnosed: a cross-sectional study in Denmark. HIV Med 2010;11:46-53
14. Emlet CA. An examination of the social networks and social isolation in older and younger adults living with HIV/AIDS. Health Soc Work 2006;31:299-308
15. Malaspina L, Woods SP, Moore DJ, et al. Successful cognitive aging in persons living with HIV infection. J Neurovirol 2011;17:110-9
16. http://www.europeanaidsclinicalsociety.org/guidelinespdf/ 2_Non_Infectious_Co_Morbidities_in_HIV.pdf (last checked 5 April 2011)
17. http://www.cancerscreening.nhs.uk/bowel/bowel-ipc-booklet.pdf (last checked 5 April 2011)
18. Fakoya A, Lamba H, Mackie N, et al. British HIV Association, BASHH and FSRH guidelines for the management of the sexual and reproductive health of people living with HIV infection 2008. HIV Med 2008;9:681-720
19. Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme information for primary care; PSA testing in asymptomatic men. Evidence document. NHS Cancer Screening Programmes, 2010. See http:// www.cancerscreening.nhs.uk/prostate/pcrmp-guide-2.html (last checked 16 July 2012)
20. Shiels MS, Goedert JJ, Moore RD, et al. Reduced risk of prostate cancer in U.S. men with AIDS. Cancer Epidemiol Biomarkers Prev 2010;19:2910-5
21. Wunder D, Bersinger NA, Fux CA, et al. Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy. Antivir Ther 2007;12:261-5
22. Duprez D, Neuhaus J, Baker J, et al. Prognostic Value of Apolipoprotein B/A1 Ratio, Total Cholesterol/HDL Ratio, and Small LDL/HDL Particle Concentrations for CHD in HIV{thorn} Participants in the SMART Study: A Nested Case-control Study. CROI 2011; abstract 807
23. British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1-52
24. Friis-Møller N, Thiébaut R, Reiss P, et al. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010;17:491-501
25. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336-45
26. Falcone EL, Mangili A, Skinner S, et al. Framingham risk score and early markers of atherosclerosis in a cohort of adults infected with HIV. Antivir Ther 2011;16:1-8
27. Lo J, Abbara S, Shturman L, et al. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. AIDS 2010;24:243-53
28. Hsue P, Ordovas K, Lee T, et al. Markedly increased carotid intima-media thickness in the absence of coronary calcium among HIV-infected individuals. Circulation 2010;122:A10273
29. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20:2165-74
30. Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalised anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092-7
31. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606-13
32. Royle J, Lincoln NB. The Everyday Memory Questionnaire-revised: development of a 13-item scale. Disabil Rehabil 2008;30:114-21
33. Sacktor NC, Wong M, Nakasujja N, et al. The International HIV Dementia Scale: a new rapid screening test for HIV dementia. AIDS 2005;19:1367-74
34. Rodriguez-Novoa S, Labarga P, Soriano V. Pharmacogenetics of tenofovir treatment. Pharmacogenomics 2009;10:1675-85
35. Avihingsanon A, van der Lugt J, Kerr S, et al. Impact of age on pharmacokinetics of boosted atazanavir 300/100 in Thai HIV-infected patients. J Int AIDS Soc 2008;11(Suppl. 1):P244
36. Crawford KW, Spritzler J, Kalayjian RC, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses 2010;26:635-43
37. Dickinson L, Jackson A, Garvey L, et al. Population pharmacokinetic modelling of plasma and intracellular once daily ritonavir-boosted darunavir in HIV-infected patients. Twelvth International Workshop on Clinical Pharmacology of HIV Therapy, 13-15 April 2011, Miami. Abstract O_12
38. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr 2006;41:461-7
39. Burford DC, Kirby M, Austoker J. Prostate Cancer Risk Management Programme: information for primary care; PSA testing in asymptomatic men. NHS Cancer Screening Programmes, 2009
40. Ahmed A, Dickinson L, Cevik M, et al. Efavirenz and darunavir plasma concentrations in HIV infected patients aged 50 years or over. Thirteenth European AIDS Conference, 12-15 October 2011, Belgrade, Serbia. Abstract PE 6.2/1
41. Goedal L, Crawford KW, Flexner C, et al. Impact of age on renal function in patients receiving tenofovir. International Workshop on Clinical Pharmacology of HIV Therapy. 8 April 2010
42. Cevik M, Dickinson L, Ahmed A, et al. Tenofovir (TFV) pharmacokinetics (PK) in HIV infected individuals over 40 years of age. Thirteenth European AIDS Conference, 12-15 October 2011, Belgrade, Serbia. Abstract PS 6/1